In this episode of our clinical case discussion podcast, experts explore second-line and salvage treatment options for patients with advanced urothelial cancer. Gain up-to-date information on novel treatment options for patients who have progressed after first-line therapy 

 In this episode of a series of podcasts exploring treatment options for patients with advanced urothelial cancer, our experts discuss the options for a patient who has previously undergone surgery, and is ineligible for cisplatin-based treatment. Learn about the latest treatment recommendations and the impact on patient outcomes.  

 In this episode of our podcast series exploring the best treatment strategies for patients with advanced urothelial cancer, our two experts discuss the most appropriate treatment for a patient with locally advanced urothelial cancer. Listen in to hear what therapy the experts would recommend for this patient.  

In this first of a series of advanced urothelial cancer clinical case discussions, two experts discuss the first-line treatment strategy for a newly-diagnosed patient who is eligible for cisplatin-based chemotherapy. Listen in to hear evidence-based views on the best treatment approach for this patient. 

Clinicians face challenging decisions on what treatment strategies to use after progression on combination therapy. Also, adverse event management is an important aspect of patient care. Dr. Manuela Schmidinger and Dr. Bernard Escudier discuss the most effective treatment options in this setting and strategies for managing adverse events. 

Combinations of ICIs or ICIs with TKIs are now part of the first-line treatment strategy, based on the results of phase III trials. The burning question in clinical practice is whether one ICI-based combination is superior to other regimens. Dr. Manuela Schmidinger and Dr. Bernard Escudier discuss these combinations and the optimal sequence of drugs. 

The benefit of adjuvant therapy in preventing or delaying recurrence and improving survival for patients with localized or locally advanced RCC remains debatable. Dr. Manuela Schmidinger and Dr. Bernard Escudier discuss this hot topic. 

 With immunotherapy shifting to the frontline setting, clinicians face challenging decisions on how to treat patients after progression. Novel treatments are being developed with promising data. Dr. Tom Powles and Dr. Joaquim Bellmunt discuss the options available and this exciting area of research.

Several clinical trials are underway to evaluate ICIs in the neoadjuvant setting, and recent data indicate that adjuvant therapy may improve survival in patients with advanced urothelial cancer. Dr. Tom Powles and Dr. Joaquim Bellmunt discuss the latest evidence. 

ICIs have been approved as front-line treatment for certain patient populations, and ICI as maintenance therapy has also been approved. Several randomized phase III trials are underway investigating the use of ICIs in the first-line setting. Dr. Tom Powles and Dr. Joaquim Bellmunt discuss the latest data and how this impacts patient care.